A Phase I, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD4954 Following Single and Multiple Ascending Dose Administration to Healthy Participants With or Without Elevated Lp(a) Levels
Latest Information Update: 27 May 2025
At a glance
- Drugs AZD 4954 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors AstraZeneca
Most Recent Events
- 27 May 2025 New trial record